RIPK1 in Diffuse Glioma Pathology: From Prognosis Marker to Potential Therapeutic Target

Area of Science:

• Neuro-oncology
• Molecular Biology
• Cancer Research

Background:

• Diffuse gliomas (DGs) are aggressive primary brain tumors arising from glial cells.
• Receptor-interacting protein kinase 1 (RIPK1) is implicated in cellular pathways relevant to cancer.
• Understanding RIPK1's role is crucial for developing targeted therapies for DGs.

Purpose of the Study:

• To investigate the role and prognostic significance of Receptor-interacting protein kinase 1 (RIPK1) in diffuse gliomas (DGs).
• To evaluate the therapeutic potential of targeting RIPK1 in glioblastoma models.

Main Methods:

• Analysis of RIPK1 mRNA expression in The Cancer Genome Atlas (TCGA) database (670 patients).
• Transcriptomic analysis using USC Xena and R.
• In vitro studies using U251 glioblastoma cells treated with a RIPK1 inhibitor (GSK2982772) and cisplatin.

Main Results:

• Elevated RIPK1 expression was associated with significantly lower patient survival probability.
• RIPK1 expression was higher in wild-type IDH (wtIDH) samples compared to mutant IDH (mIDH) samples.
• Differences in gene expression related to cellular dedifferentiation, inflammation, cell death, and immune infiltration were observed between high- and low-RIPK1 groups.
• Combined RIPK1 inhibition and cisplatin treatment reduced glioblastoma cell proliferation and enhanced apoptosis.

Conclusions:

• Overexpression of RIPK1 is linked to poor prognosis in diffuse gliomas.
• RIPK1 plays a critical role in glioma pathogenesis.
• Targeting RIPK1, potentially in combination with chemotherapy, represents a promising therapeutic strategy for DGs.